Services will hold a public meeting of its Committee on Health Data Standards and HHS Health Data Standards Implementation Teams.

Time and Date: 9:00 a.m.–5:00 p.m., July 9, 1997.

Place: Natcher Center Auditorium, Natcher Building and Conference Center, National Institutes of Health, Bethesda, Maryland.

The Natcher Center is located on the NIH campus on Center Drive off Wisconsin Avenue. The closest Metro stop is Medical Center (on the Red Line). Attendees are urged to use Metro because visitor parking at NIH is extremely limited. A map of the NIH campus is available on the World Wide Web at: http://www.nih.gov/welcome/images/nihmap.gif

Status: Open.

Purpose: The purpose of the meeting is for representatives of the U.S. Department of Health and Human Services to meet with interested and affected parties and members of the general public to describe the current status of activities relating to the adoption of health data standards pursuant to the administrative simplification provisions of Public Law 104–191, the Health Insurance Portability and Accountability Act of 1996 (HIPAA). HHS representatives will describe the HIPAA requirements for health data standards and will provide an overview of HHS efforts in implementing the law. The role of the National Committee on Vital and Health Statistics also will be described. Representatives of each of the six HHS Implementation Teams will then offer presentations on their progress to date as well as their preliminary findings relating to standards, and will respond to questions from the public.

Tentative Agenda

I. Welcome and Introductions
II. HIPAA Administrative Simplification Provisions: Background and Requirements
III. Role of the NCVHS
IV. Reports from the HHS Implementation Teams (Each report will be followed by questions from attendees.)
- Infrastructure and Crosscutting Issues
- Claims and Encounter Standards
- Unique Health Identifiers
- Enrollment and Eligibility Standards
- Coding and Classification Standards
- Security Standards

V. Conclusions

The order of agenda items is subject to change. For the final agenda, please visit the HHS Data Council's Home Page at: http://aspe.os.dhhs.gov/datacncl/

Contact Person for More Information: Additional information may be obtained from Bill Braithwaite, Office of the Assistant Secretary for Planning and Evaluation, DHHS, Room 440–D, Humphrey Building, 200 Independence Avenue S.W., Washington, D.C. 20201, telephone (202) 260–0546, or Robert Moore, Health Care Financing Administration, DHHS, 7500 Security Blvd., Baltimore, Maryland 21244, telephone (410) 786–0948.

Dated: June 19, 1997.

James Scanlon,

Director, Division of Data Policy, OPS, Office of the Assistant Secretary for Planning and Evaluation.

[FR Doc. 97–16678 Filed 6–24–97; 8:45 am]

BILLING CODE 4151–04–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 93G–0359]

Stork CFT B.V.; Withdrawal of GRAS Affirmation Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the withdrawal, without prejudice to a future filing, of a petition (GRASP 3G0397) proposing that the use of collagen fiber for use as an ingredient in human food be affirmed as generally recognized as safe (GRAS).

FOR FURTHER INFORMATION CONTACT: Mary E. LaVecchia, Center for Food Safety and Applied Nutrition (HFS–215), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–418–3072.

SUPPLEMENTARY INFORMATION: In a notice published in the **Federal Register** of December 3, 1993 (58 FR 63996), FDA announced that a petition (GRASP 3G0397) had been filed by Teepak, Inc. (now Stork CFT B.V.), c/o 1001 G St. NW., suite 500 West, Washington, DC 20001. The petition proposed that collagen fiber be affirmed as GRAS for use as an ingredient in human food. Stork CFT B.V., (formerly Teepak, Inc.) has now withdrawn the petition without prejudice to a future filing (21 CFR 171.7).

Dated: June 13, 1997.

Alan M. Rulis,

Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.

[FR Doc. 97–16685 Filed 6–24–97; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 87N–0262]

Merck & Co., Inc., et al.; Withdrawal of Approval of 39 New Drug Applications, 13 Abbreviated Antibiotic Applications, and 46 Abbreviated New Drug Applications

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of 39 new drug applications (NDA's), 13 abbreviated antibiotic applications (AADA's), and 46 abbreviated new drug applications (ANDA's). The holders of the applications notified the agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.

EFFECTIVE DATE: July 25, 1997.

FOR FURTHER INFORMATION CONTACT: Olivia A. Vieira, Center for Drug Evaluation and Research (HFD–7), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–594–2041.

SUPPLEMENTARY INFORMATION: The holders of the applications listed in the table in this document have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications. The applicants have had a hearing or have, by their request, waived their opportunity for a hearing.

Application No.	Drug	Applicant
NDA 1–205	Propadrine (Phenylephrine hydrochloride) Elixir	Merck & Co., Inc., P.O. Box 4, BLA–20, West Point, PA 19486.
NDA 5–151	Percorten Acetate (desoxy-corticosterone acetate, USP Pellets.	Novartis, 556 Morris Ave., Summit, NJ 07901–1395.
NDA 5–587	Phisoderm Cream	Sterling Drug, Inc., 90 Park Ave., New York, NY 10016.
NDA 5–786	Ceepryn Concentrate Solution	Merrell Dow Research Institute, 2110 E. Galbraith Rd., Cincinnati, OH 45215–6300.